- Joined
- Aug 17, 2020
- Posts
- 13,207
- Reaction score
- 16,658
- Bookie:
- $ 1,354.00
@occupant told me about the carnage he saw from COVID on X-Rays of the ravaged. You just don't see cell damage and hemorrhaging like that from a cytokine storm from the flu. They're getting to the short strokes now to fix everything.It's all very interesting. The same company that makes the antiviral I mentioned above also makes the leading drug for bradykinin. (which causes low blood pressure and gross swelling) The company has been working with Fauci for years and his NIAID has paid for most of the studies lately. The drug, Berotrlstat, is will be finally approved and for sale in December.
Berotralstat for HAE Attacks to Get FDA Review, BioCryst Says
The FDA accepted BioCryst's new drug application for berotralstat to treat HAE attacks, with a decision expected by December.angioedemanews.com
“We are sharply focused on building out a very experienced commercial team and executing our commercial plan, so we are ready to go fast when we get approval,” he said.
HAE patients produce too much of an inflammatory molecule called bradykinin, causing blood vessels to dilate and leading to episodes of swelling and pain.
Berotralstat is an oral inhibitor of plasma kallikrein, a precursor of bradykinin, and is expected to treat or prevent angioedema attacks by lowering the amount of bradykinin in people with HAE.
But the stock sits there like nothing is happening. It's surreal. I'm not sure WTF is going on. Either nobody seems to get it and it'll jump 10 fold one day...or I don't know shit. Either you pal Juice juice told you about a 10-banger, or he totally trippin.
The answer is treating everyone testing positive with Galidesivir. People who still get really sick should be treated with a good steroid and an HAE drug like Berotralstat. Done.
Is a Bradykinin Storm Brewing in COVID-19?
Excess of the inflammatory molecule bradykinin may explain the fluid build-up in the lungs of patients with coronavirus infections. Clinical trials of inhibitors are putting this hypothesis to the test.
www.the-scientist.com
Last edited:
